Start a conversation ↗Knowledge centre
Selected developments shaping clinical research, bioequivalence and the regulatory environment in Malaysia, ASEAN and beyond.
Latest intelligence
Regional clinical-trial and pharmaceutical developments
Immunotherapy in Asia: current insights and prospects in Southeast Asia and Malaysia - FrontiersMalaysia to set up rare disease registry - Free Malaysia TodayMalaysia’s Evolving Rare Disease Ecosystem and the Future of Orphan Drug Access - BioSpectrum AsiaA systematic review and meta-analysis of pharmacy education and practice on prevention and management of noncommunicable diseases in ASEAN countries - NatureMethods, products and development strategy
Complex Generics: Facts, Figures and Who They Benefit - Teva PharmaceuticalsEMA adopts five product-specific bioequivalence guidelines - Generics and Biosimilars InitiativeSix business lessons from Cipla’s nine-decade journey - Express PharmaBranded Generic Market Size And Share Report, 2026-2033 - Grand View ResearchGuidance and announcements from medicines regulators
What Eight APAC Regulators Have Actually Published on AI in Drug Development - BioPharma APACAsia-Pacific Roundup: Australia’s TGA seeks feedback on fee increases, warns of need to cut costs - RAPSQPS India Successfully Completes Week-Long US FDA Regulatory Inspection - Business WireTechnology influencing trial design and delivery
AstraZeneca and Oracle Partner to Advance AI-Powered Clinical Trials and Patient Care - EME Outlook MagazineAI Is Flooding Drug Discovery With Candidates. Clinical Validation Has No Flood Gates. - The Clinical Trial VanguardOracle, AstraZeneca Team Up to Deploy AI in Hunt for Trial Patients - finance.biggo.comAstraZeneca Partners With Oracle to Refine Clinical Research With AI - WSJ